Table 3.

Kidney Follow-Up Components

Component	Usual Care N=13	Education Alone N=18	ACT N=15	P Value
14-d provider and laboratory follow-upa	0 (0)	2 (11)	12 (80)	<0.001
30-d provider and laboratory follow-upa	0 (0)	4 (22)	12 (80)	<0.001
Laboratory monitoring
Serum creatinine
14-d	9 (69)	11 (61)	13 (87)	0.27
30-d	11 (85)	14 (78)	14 (93)	0.52
90-d	12 (92)	17 (94)	15 (100)	0.74
Time to first assessment, d	9 (7, 19)	7 (4, 16)	7 (2, 6)	0.03
Urine protein assessmentb
14-d	0 (0)	3 (17)	13 (87)	<0.001
30-d	2 (15)	5 (28)	13 (87)	<0.001
90-d	5 (39)	9 (50)	14 (93)	0.004
Time to first assessment, d	35 (28, 78)	20 (7, 52)	5.5 (2, 9)	0.001
Clinician follow-up
PCPc
14-d	11 (85)	8 (44)	14 (93)	0.003
30-d	12 (92)	11 (61)	14 (93)	0.03
Time to PCP follow-up, d	9.5 (4, 12.5)	4 (2, 16)	5 (1, 8)	0.29
Nephrologist
14-d	0 (0)	1 (6)	3 (20)	0.23
30-d	1 (8)	3 (17)	5 (33)	0.22
Time to nephrology follow-up, d	27	20 (6, 21)	14 (13, 22)	0.50
Pharmacistd
14-d	1 (8)	1 (6)	9 (60)	<0.001
30-d	1 (8)	1 (6)	11 (73)	<0.001
Time to pharmacist follow-up, d	13	10	7 (4, 13)	0.53

Note: Data reported as n (%) for nominal/discrete data or median (IQR) for continuous data.

Abbreviations: ACT, AKI in Care Transition; PCP, primary care provider.

^aCumulative incidence of provider (PCP or nephrologist) and laboratory (SCr and urine study) follow-up.

^bIncludes urinalysis with microscopy, urine dipstick, and urine albumin-to-creatinine ratio. Of the 42 urine evaluations performed across the groups within 90 days, 88% were urinalyses or urine dipsticks. In cases where results revealed an elevated protein osmolality ratio or hematuria on screening evaluation with a urinalysis with microscopy or urine dipstick, a repeat assessment and urine albumin-to-creatinine ratio were recommended within 3 months of discharge.

^cTelehealth visit occurred in 1 and 4 participants in the Usual Care and Education Alone groups, respectively.

^dTelehealth visit occurred in 1 participant in the ACT group.